Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Drops 36.4%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 119,457 shares, a decrease of 36.4% from the September 15th total of 187,942 shares. Based on an average trading volume of 69,825 shares, the short-interest ratio is currently 1.7 days. Approximately 6.6% of the company’s shares are short sold.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO opened at $1.70 on Friday. Aptevo Therapeutics has a 52-week low of $1.37 and a 52-week high of $29.70. The business’s 50 day moving average is $2.23 and its two-hundred day moving average is $3.79.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.02) by $0.71. Sell-side analysts expect that Aptevo Therapeutics will post -17.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to harness the immune system by directing immune cells toward specific disease-associated targets.

Aptevo’s pipeline is built primarily around its proprietary ADAPTIR bispecific antibody technology, which is intended to create therapeutic antibodies capable of binding to two different targets.